Compare ASTRAZENECA PHARMA with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DR. DATSONS LABS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DR. DATSONS LABS ASTRAZENECA PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 114.8 -10.9 - View Chart
P/BV x 35.1 0.2 21,644.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
DR. DATSONS LABS
Mar-14
ASTRAZENECA PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,278126 1,017.5%   
Low Rs88331 2,856.3%   
Sales per share (Unadj.) Rs228.4133.0 171.7%  
Earnings per share (Unadj.) Rs10.40.2 6,835.9%  
Cash flow per share (Unadj.) Rs16.36.6 246.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8128.8 76.7%  
Shares outstanding (eoy) m25.0031.66 79.0%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x4.70.6 803.9%   
Avg P/E ratio x104.2516.1 20.2%  
P/CF ratio (eoy) x66.411.8 561.0%  
Price / Book Value ratio x10.90.6 1,800.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0082,477 1,090.2%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,53556 2,741.6%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,7104,211 135.6%  
Other income Rs m12379 155.7%   
Total revenues Rs m5,8334,289 136.0%   
Gross profit Rs m463569 81.4%  
Depreciation Rs m147204 72.1%   
Interest Rs m0430 0.0%   
Profit before tax Rs m43813 3,448.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1796 2,932.8%   
Profit after tax Rs m2595 5,397.9%  
Gross profit margin %8.113.5 60.0%  
Effective tax rate %40.848.0 85.0%   
Net profit margin %4.50.1 3,980.4%  
BALANCE SHEET DATA
Current assets Rs m3,2096,852 46.8%   
Current liabilities Rs m2,0706,711 30.8%   
Net working cap to sales %20.03.3 596.0%  
Current ratio x1.61.0 151.9%  
Inventory Days Days72161 45.0%  
Debtors Days Days35318 11.0%  
Net fixed assets Rs m7903,673 21.5%   
Share capital Rs m50317 15.8%   
"Free" reserves Rs m2,4193,761 64.3%   
Net worth Rs m2,4694,078 60.6%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m4,60512,633 36.5%  
Interest coverage xNM1.0-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.20.3 372.0%   
Return on assets %5.63.4 163.4%  
Return on equity %10.50.1 8,913.5%  
Return on capital %17.77.7 231.2%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m300964 31.1%   
Fx outflow Rs m2,015607 331.9%   
Net fx Rs m-1,715357 -480.6%   
CASH FLOW
From Operations Rs m881,345 6.5%  
From Investments Rs m-94-2,256 4.1%  
From Financial Activity Rs mNA-1,200 0.0%  
Net Cashflow Rs m-6-2,111 0.3%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 1.4 1,163.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 94.1 9.7%  
Shareholders   12,856 20,807 61.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tumbles 800 Points Tracking Global Selloff; Banking & Finance Stocks Bleed(09:30 am)

Asian stock markets opened sharply lower today after Wall Street's main indexes tumbled, with technology-related stocks under pressure following a steep rise in benchmark US Treasury yields.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 26, 2021 10:14 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS